

# JÃ¼rgen Finke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3257214/publications.pdf>

Version: 2024-02-01

191  
papers

7,360  
citations

71102

41  
h-index

62596

80  
g-index

192  
all docs

192  
docs citations

192  
times ranked

7360  
citing authors

#	ARTICLE	IF	CITATIONS
1	Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. <i>Lancet Oncology</i> , The, 2009, 10, 855-864.	10.7	620
2	Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party. <i>Journal of Clinical Oncology</i> , 2007, 25, 4938-4945.	1.6	446
3	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , the, 2016, 3, e217-e227.	4.6	442
4	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2016, 374, 43-53.	27.0	436
5	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575.	13.7	328
6	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	1.4	278
7	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , the, 2017, 4, e510-e523.	4.6	258
8	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019, 25, 603-611.	30.7	253
9	2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. <i>Cancer</i> , 2001, 91, 889-899.	4.1	221
10	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	30.7	216
11	Oncogenic JAK2 <sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	166
12	Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change. <i>Journal of Clinical Oncology</i> , 2013, 31, 3259-3271.	1.6	137
13	High-dose chemotherapy with autologous haematopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. <i>Lancet Haematology</i> , the, 2016, 3, e388-e397.	4.6	128
14	Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 988-997.e6.	2.9	123
15	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. <i>Blood</i> , 2019, 134, 892-899.	1.4	110
16	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <i>JAMA Oncology</i> , 2018, 4, 1245.	7.1	97
17	Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haematopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. <i>Lancet Haematology</i> , the, 2017, 4, e293-e301.	4.6	83
18	Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 237-245.	3.5	82

#	ARTICLE	IF	CITATIONS
19	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia â€” a matched pair analysis by the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2019, 184, 782-787.	2.5	82
20	Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. <i>British Journal of Haematology</i> , 1996, 95, 715-723.	2.5	81
21	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2015, 171, 239-246.	2.5	80
22	Matched and Mismatched Allogeneic Stem-Cell Transplantation From Unrelated Donors Using Combined Graft-Versus-Host Disease Prophylaxis Including Rabbit Anti-T Lymphocyte Globulin. <i>Journal of Clinical Oncology</i> , 2003, 21, 506-513.	1.6	71
23	Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAIN trial. <i>Haematologica</i> , 2012, 97, e34-e35.	3.5	68
24	Haploidentical <i>versus</i> unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2019, 104, 524-532.	3.5	68
25	Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2014, 99, 916-921.	3.5	62
26	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1975-1983.	2.0	61
27	Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. <i>Bone Marrow Transplantation</i> , 2018, 53, 565-575.	2.4	60
28	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. <i>Bone Marrow Transplantation</i> , 2019, 54, 44-52.	2.4	59
29	Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1716-1726.	2.0	55
30	Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 489-495.	2.0	53
31	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphomaâ€”a randomized phase III trial (MATRix). <i>BMC Cancer</i> , 2016, 16, 282.	2.6	53
32	Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. <i>Haematologica</i> , 2019, 104, 370-379.	3.5	53
33	Severe veno-occlusive disease after allogeneic bone marrow or peripheral stem cell transplantation â€” role of transjugular intrahepatic portosystemic shunt (TIPS). <i>Liver</i> , 2001, 21, 31-36.	0.1	51
34	Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2018, 11, 55.	17.0	51
35	Allogeneic Stem Cell Transplantation for Patients Age â‰¥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 44-52.	2.0	49
36	Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Haematologica</i> , 2019, 104, 1782-1788.	3.5	48

#	ARTICLE	IF	CITATIONS
37	GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. <i>Lancet Haematology</i> ,the, 2019, 6, e89-e99.	4.6	47
38	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.	7.2	47
39	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. <i>Lancet Haematology</i> ,the, 2015, 2, e384-e392.	4.6	46
40	Genome-wide Profiling in AML Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1450-1459.e1.	2.0	45
41	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1406-1414.	2.0	44
42	Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 476-488.	1.3	43
43	Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2558-2567.	2.0	43
44	Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628). <i>BMC Cancer</i> , 2018, 18, 1132.	2.6	41
45	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e128-e140.	2.0	40
46	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021, 96, 69-79.	4.1	40
47	High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 2015, 56, 3295-3300.	1.3	39
48	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. <i>Blood Cancer Journal</i> , 2019, 9, 88.	6.2	39
49	Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 130.	17.0	38
50	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 215-223.	2.4	36
51	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016, 101, 773-780.	3.5	35
52	Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia. <i>Journal of Clinical Investigation</i> , 2020, 130, 1315-1329.	8.2	35
53	Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 997-1003.	4.1	34
54	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. <i>Blood Advances</i> , 2018, 2, 2127-2135.	5.2	34

#	ARTICLE	IF	CITATIONS
55	Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 1499-1510.	2.4	34
56	High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. <i>Blood Advances</i> , 2020, 4, 3378-3381.	5.2	34
57	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021, 35, 215-224.	7.2	34
58	Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR. <i>Annals of Hematology</i> , 2016, 95, 739-744.	1.8	32
59	Ruxolitinib+EC combination treatment for refractory severe chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 909-916.	2.4	32
60	Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2017, 123, 1965-1970.	4.1	31
61	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 186, 767-776.	2.5	31
62	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 114-120.	2.0	27
63	Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with <scp>CLL</scp>: a retrospective analysis from the European Society for Blood and Marrow Transplantation (<scp>EBMT</scp>). <i>British Journal of Haematology</i> , 2017, 178, 521-533.	2.5	26
64	Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 641-647.	2.3	25
65	Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e204-e208.	2.0	23
66	Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2015, 126, 863-863.	1.4	23
67	Horizontal DNA Transfer from Donor to Host Cells as an Alternative Mechanism of Epithelial Chimerism after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 319-329.	2.0	22
68	A Wild Bootstrap Approach for the Aalen-Johansen Estimator. <i>Biometrics</i> , 2018, 74, 977-985.	1.4	22
69	The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1662-1667.	2.4	22
70	Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. <i>BMC Cancer</i> , 2019, 19, 287.	2.6	22
71	Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. <i>Oncotarget</i> , 2017, 8, 112972-112979.	1.8	22
72	Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. <i>Haematologica</i> , 2014, 99, 1492-1498.	3.5	19



#	ARTICLE	IF	CITATIONS
73	Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantation. <i>Clinical Biochemistry</i> , 2018, 52, 137-141.	1.9	19
74	Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study. <i>Blood</i> , 2018, 132, 818-818.	1.4	19
75	Relevance of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) On Non-Relapse Related Mortality (NRM) in Patients with Acute Lymphoblastic Leukemia (ALL) Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Complete Remission: Results From the GMALL Study Group. <i>Blood</i> , 2009, 114, 3352-3352.	1.4	18
76	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50Äyearsâ€”a report from the EBMT acute leukemia working party. <i>Journal of Hematology and Oncology</i> , 2016, 9, 65.	17.0	17
77	FLAMISA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2165-2173.	2.0	17
78	Second allogeneic haematopoietic cell transplantation using HLAÄ€matched unrelated <i>versus</i> TÄ€cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	2.5	17
79	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of <scp>EBMT</scp> and the Spanish Myelofibrosis Registry. <i>American Journal of Hematology</i> , 2021, 96, 1186-1194.	4.1	17
80	Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2251-2260.	2.0	16
81	Comparative outcomes of myeloablative and reducedÄ€intensity conditioning allogeneic hematopoietic cell transplantation for therapyÄ€related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation. <i>American Journal of Hematology</i> , 2019, 94, 431-438.	4.1	16
82	Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis. <i>Annals of Hematology</i> , 2021, 100, 2339-2350.	1.8	16
83	A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 2404-2414.	1.3	15
84	Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma. <i>Blood</i> , 2021, 138, 6-6.	1.4	15
85	Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 4258-4266.	7.0	15
86	Improved analysis of TCRÎ³ variable region expression in humans. <i>Journal of Immunological Methods</i> , 2016, 434, 66-72.	1.4	14
87	Phenotypical and functional analysis of donor lymphocyte infusion products after long-term cryopreservation. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102594.	1.0	14
88	BCL-2 Induction is Part of the Strategy of Epstein-Barr Virus. <i>Leukemia and Lymphoma</i> , 1994, 12, 413-419.	1.3	13
89	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 683-691.	2.4	13
90	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. <i>Blood</i> , 2016, 128, 511-511.	1.4	13

#	ARTICLE	IF	CITATIONS
91	Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. <i>Blood</i> , 2022, 140, 1408-1418.	1.4	13
92	Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia—A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 667-675.e2.	0.4	12
93	Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 55.	3.7	12
94	An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 363-9.	2.3	11
95	Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia—A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2017, 92, 18-22.	4.1	11
96	Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. <i>Bone Marrow Transplantation</i> , 2020, 55, 224-232.	2.4	11
97	Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 416-422.	2.4	11
98	Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 414-423.	3.5	10
99	Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis. <i>British Journal of Haematology</i> , 2020, 190, e110-e114.	2.5	10
100	Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT—A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party. <i>Frontiers in Immunology</i> , 2020, 11, 586.	4.8	10
101	The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (<sc>ALWP</sc>) of the <sc>European group for blood and marrow transplantation (EBMT)</sc>. <i>American Journal of Hematology</i> , 2021, 96, 40-50.	4.1	10
102	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	2.4	10
103	Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib. <i>Blood</i> , 2016, 128, 4561-4561.	1.4	10
104	DNA chimerism and its consequences after allogeneic hematopoietic cell transplantation. <i>Chimerism</i> , 2011, 2, 25-28.	0.7	9
105	Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. <i>Leukemia Research</i> , 2020, 98, 106454.	0.8	8
106	Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 110-120.	2.4	8
107	Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 768-774.	2.4	8
108	Clonal hematopoiesis of indeterminate potential in older patients having received an allogeneic stem cell transplantation from young donors. <i>Bone Marrow Transplantation</i> , 2020, 55, 665-668.	2.4	7

#	ARTICLE	IF	CITATIONS
109	The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2020, 95, 282-294.	4.1	7
110	Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers. <i>Blood</i> , 2014, 124, 2554-2554.	1.4	7
111	Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT. <i>Blood</i> , 2016, 128, 4657-4657.	1.4	7
112	Autologous Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT. <i>Blood</i> , 2016, 128, 678-678.	1.4	7
113	Reduced Toxicity Conditioning with Treosulfan and Fludarabine in Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: Results of an International Prospective Phase II Trial.. <i>Blood</i> , 2008, 112, 3274-3274.	1.4	7
114	MiR-146a Regulates the TRAF6/TNF-Axis in Donor T Cells during Graft-Versus-Host Disease. <i>Blood</i> , 2014, 124, 843-843.	1.4	7
115	A fast and simple approach for the simultaneous detection of hematopoietic chimerism, NPM1, and FLT3-ITD mutations after allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2014, 93, 293-298.	1.8	6
116	Cytogenetic risk score maintains its prognostic significance in <sc>AML</sc> patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1135-1141.	4.1	6
117	Relapse- and Immunosuppression-Free Survival after Hematopoietic Stem Cell Transplantation: How Can We Assess Treatment Success for Complex Time-to-Event Endpoints?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 992-997.	2.0	6
118	Feasibility and Outcomes of a Third Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 408.e1-408.e6.	1.2	6
119	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2445-2453.	2.4	6
120	Comparison of fludarabine+melphalan and fludarabine+treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 1269-1276.	2.4	6
121	Analysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: âœreal lifeâœevaluation. <i>Annals of Hematology</i> , 2016, 95, 457-463.	1.8	5
122	Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects. <i>Haematologica</i> , 2018, 103, 1527-1534.	3.5	5
123	Blastic transformation of <i>BCR-ABL1</i> positive chronic myeloid leukaemia through acquisition of <i>CBFB-MYH11</i> and mutant <i>KIT</i>. <i>British Journal of Haematology</i> , 2020, 190, e339-e343.	2.5	5
124	Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 327-333.	2.4	5
125	Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1116-1123.	2.4	5
126	Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers. <i>Blood</i> , 2008, 112, 329-329.	1.4	4



#	ARTICLE	IF	CITATIONS
127	Allogeneic Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT. <i>Blood</i> , 2016, 128, 681-681.	1.4	4
128	Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1072-1078.	2.4	4
129	Response to JAK 1/2 Inhibition in Patients with Corticosteroid-Refractory Acute Graft-Versus-Host Disease. <i>Blood</i> , 2014, 124, 3934-3934.	1.4	3
130	Treatment of Corticosteroid-Refractory Graft-Versus-Host Disease with Ruxolitinib in 95 Patients. <i>Blood</i> , 2015, 126, 858-858.	1.4	3
131	A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT. <i>Annals of Hematology</i> , 2021, 100, 2095-2103.	1.8	2
132	Diagnostic and therapeutic challenge of unclassifiable enteropathies with increased intraepithelial CD103+ CD8+ T lymphocytes: a single center case series. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 889-898.	1.5	2
133	<sup>18</sup> F-fluoro- <sup>2</sup> -deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. <i>Cancer</i> , 2001, 91, 889-899.	4.1	2
134	Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial. <i>Blood</i> , 2013, 122, 4384-4384.	1.4	2
135	Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from		

#	ARTICLE	IF	CITATIONS
145	Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis. <i>Blood</i> , 2015, 126, 3209-3209.	1.4	1
146	Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 63-63.	1.4	1
147	Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Registry Study of the German Stem Cell Transplant Registry (DRST) of the German Working Group for Blood and Marrow Transplantation (DAG-KBT). <i>Blood</i> , 2016, 128, 2304-2304.	1.4	1
148	Retrospective Comparison of Using or Not Using Donor Lymphocyte Transfusion in the Treatment of Hematological Relapse after Allogeneic Stem Cell Transplantation in 489 Adults with Acute Myeloid Leukemia.. <i>Blood</i> , 2004, 104, 298-298.	1.4	1
149	Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia (ALL) in First Complete Remission (CR1).. <i>Blood</i> , 2008, 112, 1966-1966.	1.4	1
150	Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 566-566.	1.4	1
151	Genital Mucosa in Men Is a Frequent Target of Chronic Graft Versus Host Disease. <i>Blood</i> , 2012, 120, 4183-4183.	1.4	1
152	Immunohistochemical Expression of TCR $\beta$ Predicts Achievement of Complete Remission in Enteropathy-Associated T-Cell Lymphoma. <i>Blood</i> , 2012, 120, 5101-5101.	1.4	1
153	Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT. <i>Blood</i> , 2015, 126, 4390-4390.	1.4	1
154	Quality of Life in Patients with Primary CNS Lymphoma - a Pooled Analysis from Three Prospective Multicentre Trials. <i>Blood</i> , 2016, 128, 5385-5385.	1.4	1
155	Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in Europe between 1995-2018: An EBMT Retrospective Analysis. <i>Blood</i> , 2020, 136, 38-39.	1.4	1
156	Favourable outcomes of double $\lambda$ /double $\kappa$ expressor lymphoma and high $\lambda$ grade B $\lambda$ cell lymphoma, not otherwise specified after early dose $\lambda$ intensive treatment and up $\lambda$ front autologous stem cell transplantation: a single $\lambda$ centre retrospective experience. <i>British Journal of Haematology</i> , 0, , .	2.5	1
157	Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	1
158	Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation. <i>Cancers</i> , 2022, 14, 3307.	3.7	1
159	Frequent Genomic Alterations in Epithelium Measured by Microsatellite Instability Following Allogeneic Hematopoietic Cell Transplantation in Humans.. <i>Blood</i> , 2005, 106, 1117-1117.	1.4	0
160	SELDI-TOF-Based Proteomic Analysis of Plasma Samples as a Diagnostic Tool to Predict Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 1165-1165.	1.4	0
161	â€œATG16 L1 a Additional Risk Factor for TRM After allogeneic Stem Cell Transplantationâ€œ. <i>Blood</i> , 2009, 114, 1155-1155.	1.4	0
162	High Impact of Human Leukocyte Antigen Matching On Overall Survival and Transplant Related Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Long-Term Study From the EBMT Registry.. <i>Blood</i> , 2009, 114, 2286-2286.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Chronic Graft-Versus-Host Disease: Lessons From a Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation (HSCT) From Matched Unrelated Donors. Blood, 2010, 116, 212-212.	1.4	0
164	Second Allogeneic Stem Cell Transplantation (allo-SCT) Using Reduced-Intensity Conditioning (RIC) for Acute Myeloid Leukemia (AML) Patients Who Relapsed Following a First RIC Allo-SCT: a Survey From the Acute Leukemia Working Party of EBMT.. Blood, 2010, 116, 3447-3447.	1.4	0
165	Pulmonary Graft-Versus-Host Disease After Reduced Toxicity Conditioning with Fludarabin, Carmustine and Melphalan Prior to Hematopoietic Stem Cell Transplantation. Blood, 2010, 116, 1266-1266.	1.4	0
166	Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. Blood, 2010, 116, 680-680.	1.4	0
167	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1) At the Era of Tyrosine Kinase Inhibitors (TKI): A Survey From the Acute Leukemia Working Party (ALWP) of EBMT., Blood, 2011, 118, 4107-4107.	1.4	0
168	Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT. Blood, 2011, 118, 3004-3004.	1.4	0
169	Combined Effect of Mtor Inhibitors and FTI for the Growth Inhibition of T Cell Lymphoma - Involvement of Different Molecular Mechanisms According to the Lymphoma Subtype. Blood, 2012, 120, 4870-4870.	1.4	0
170	Autologous Stem Cell Transplantation (ASCT) for Enteropathy-Associated T-Cell Lymphoma (EATL): Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2012, 120, 3105-3105.	1.4	0
171	High-Dose Therapy and Autologous Stem Cell Transplantation for Extra-Nodal NK/T Lymphoma in Western Patients; A Study From the European Group for Blood and Marrow Transplantation (EBMT).. Blood, 2012, 120, 3148-3148.	1.4	0
172	Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score.. Blood, 2012, 120, 3090-3090.	1.4	0
173	Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT. Blood, 2013, 122, 2092-2092.	1.4	0
174	Second Allogeneic Stem Cell Transplantation (AlloSCT) In Patients With Relapsed Lymphoma After First Allosct. A Retrospective Study Of The EBMT Lymphoma Working Party. Blood, 2013, 122, 4632-4632.	1.4	0
175	Dose Intensification with Rituximab, MTX and CHOP Results in Superior Results for Young High Risk DLBCL Patients Than Primary Autologous Transplantation. Blood, 2015, 126, 3967-3967.	1.4	0
176	Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT. Blood, 2015, 126, 1958-1958.	1.4	0
177	Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 4316-4316.	1.4	0
178	Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 196-196.	1.4	0
179	Relapse Risk Score after Allogeneic Stem Cell Transplantation for MDS Patients. an EBMT Study from the MDS Subcommittee of Chronic Malignancies Working Party (CMWP). Blood, 2016, 128, 4701-4701.	1.4	0
180	Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.. Blood, 2016, 128, 522-522.	1.4	0

#	ARTICLE	IF	CITATIONS
181	High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group. <i>Blood</i> , 2016, 128, 781-781.	1.4	0
182	Allogeneic Hematopoietic Stem Cell Transplantation for Primary Refractory Acute Lymphoblastic Leukemia - a Report from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 4668-4668.	1.4	0
183	Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 4663-4663.	1.4	0
184	Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2019, 134, 2053-2053.	1.4	0
185	Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST). <i>Blood</i> , 2021, 138, 3926-3926.	1.4	0
186	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2021, 138, 3952-3952.	1.4	0
187	Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT. <i>Blood</i> , 2020, 136, 26-27.	1.4	0
188	NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
189	Does a Change in IPSS-R between Diagnosis and Transplant Have an Impact on Transplant Outcome in Patients with MDS? a Retrospective Analysis from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
190	Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
191	Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2020, 136, 3-4.	1.4	0